Esperion Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Esperion Therapeutics

28/02/2025 14:17

Esperion Therapeutics Inc ESPR.OQ ESPR.O is expected to show a rise in quarterly revenue when it reports  results on March 4 for the period ending December 31 2024

The Ann Arbor Michigan-based  company is expected to report a 91.0% increase in revenue to $61.585 million from $32.25 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Esperion Therapeutics Inc is for a loss of 15 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Esperion Therapeutics Inc is $5.50​, above​ its last closing price of $1.66. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.18
-0.18
-0.15
Beat
14.6
Jun. 30 2024
-0.17
-0.18
-0.33
Missed
-79.2
Mar. 31 2024
0.08
0.05
0.34
Beat
627.3​
Dec. 31 2023
-0.41
-0.48
-0.50
Missed
-3.6
​​Sep. 30 2023
-0.43
-0.43
-0.37
Beat
14.4
Jun. 30 2023
-0.62
-0.61
-0.46
Beat
24.8​
Mar. 31 2023
-0.64
-0.65
-0.79
Missed
-21.1
Dec. 31 2022
-0.82
-0.84
-0.76
Beat
9.6

This summary was machine generated February 28 at 14:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)